Asthma is a condition that most individuals can manage by using inhalers and long-acting beta-agonist drugs. However, the treatment is not universal and it has been estimated that up to 20 percent of asthma sufferers do not benefit enough (if at all) from current treatments. This may be about to change as a new treatment is being investigated. Here we explain what is currently known about Dupilumab.
Dupilumab is a treatment that contains monoclonal antibodies and is meant to be injected on a weekly basis. Monoclonal antibodies are laboratory-engineered proteins that have been created to interfere with components of the immune response. Given its broad spectrum potential, the treatment is considered for a range of conditions including; eczema, asthma and rheumatoid cancer.
To date, the treatment has only been tested in asthma sufferers that have high levels of eosinophils. This is a sub-group of asthma sufferers that is particularly known for being unable to respond well to traditional treatments. In the largest study of Dupilumab to date, the results suggested that 87% of asthma attacks were reduced. It appears that 104 participants that presented with moderate-to-severe esophilic asthma took part, and the study is yet to be published.
Given the limited sample of a broad level of severity, we would be keen to see the full publication before making any conclusions. Yet, in the context of other reports in mainstream media, it is difficult not to sprout a bit of cautious optimism. Specifically, there have been reports to suggest that Dupilumab is likely to be approved in the UK by 2018.
We will keep an eye on this development, the publications, trials and controversies that always crop up with any new treatment before it is marketed. For the time being, you can read more information here.